Please assess the completion status of the following clinical trial:

Trial Title: A Study Of PF-04171327 In The Treatment Of The Signs And Symptoms Of Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patients ≥ 18 years of age, diagnosed with rheumatoid arthritis for a minimum duration of 3 months~* On stable dose of methotrexate for at least 6 weeks prior to screening~* Patient must have minimum disease activity level of ≥ 6 tender/painful joints, ≥ 6 swollen joints and CRP ≥ 0.7 mg/dL~* Not currently receiving steroid medication~Exclusion Criteria:~* Pregnant or nursing women~* Patients that have active infections, TB, HIV and/or Hepatitis B or C~* Patients that have a history of intolerance or significant adverse effects with the use of glucocorticoids

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PF-04171327 10 mg (Type: EXPERIMENTAL): None
- PF-04171327 25 mg (Type: EXPERIMENTAL): None
- Prednisone (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).